CLINICAL TRIALS PROFILE FOR LOTRIMIN

All Clinical Trials for LOTRIMIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00835510 ↗	Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis	Completed	Taro Pharmaceuticals USA	Phase 1	2008-06-01	To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in the treatment of interdigital tinea pedis, and to show the superiority of the active treatments over that of the placebo (vehicle).
NCT01119742 ↗	Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis	Terminated	Taro Pharmaceuticals USA	Phase 1	2010-07-01	To demonstrate comparable safety and efficacy of Taro Pharmaceuticals, Inc butenafine hydrochloride cream 1% test product and Lotrimin Ultra cream (reference listed drug) in the treatment of interdigital tinea pedis, and to show the superiority of the active treatments over that of the placebo (vehicle).
NCT01580878 ↗	Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis	Completed	Taro Pharmaceuticals USA	Phase 1	2012-01-01	The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with interdigital tinea pedis. It will also be determined whether the efficacy of each of the two active treatments is superior to that of the vehicle cream (placebo).
NCT04532164 ↗	Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants	Completed	Bayer	Phase 3	2013-06-10	Allergic skin reaction can be produced by the combination of a chemical product applied to the skin and ultraviolet (UV) radiation (a type of invisible light that comes from the sun and other light sources and can hurt your skin and eyes) received by the person. The researchers in this study wanted to find out if cream V61-044 might cause an allergic skin reaction to sunlight when applied to the skin in healthy participants. Cream V61-044 (brand name: LOTRIMIN ULTRA) is an approved drug used to treat infections caused by fungi (small growing organisms such as mold, mildew, yeast or mushrooms). Participants joining this study underwent two study phases: in Induction phase, participants received the test cream and UV radiation twice a week for 3 weeks; after 10 days of rest, in Challenge phase participants received the test cream and UV radiation once again. In both phases, the test cream was applied to two test areas on the upper back of the participants and to one of the test area UV radiation was applied. Evaluation on the skin rash was conducted two days after each UV radiation.

Clinical Trial Conditions for LOTRIMIN

Condition Name

Condition Name for LOTRIMIN
Intervention	Trials
Tinea Pedis	2
Dermatitis, Photoallergic	1
Interdigital Tinea Pedis	1

Condition MeSH

Condition MeSH for LOTRIMIN
Intervention	Trials
Tinea Pedis	3
Tinea	3
Dermatitis, Photoallergic	1
Dermatitis	1

Clinical Trial Locations for LOTRIMIN

Trials by Country

Trials by Country for LOTRIMIN
Location	Trials
United States	10
Belize	1

Trials by US State

Trials by US State for LOTRIMIN
Location	Trials
New Jersey	1
Texas	1
Tennessee	1
South Carolina	1
Ohio	1

Clinical Trial Progress for LOTRIMIN

Clinical Trial Phase

Clinical Trial Phase for LOTRIMIN
Clinical Trial Phase	Trials
Phase 3	1
Phase 1	3

Clinical Trial Status

Clinical Trial Status for LOTRIMIN
Clinical Trial Phase	Trials
Completed	3
Terminated	1

Clinical Trial Sponsors for LOTRIMIN

Sponsor Name

Sponsor Name for LOTRIMIN
Sponsor	Trials
Taro Pharmaceuticals USA	3
Bayer	1

Sponsor Type

Sponsor Type for LOTRIMIN
Sponsor	Trials
Industry	4

LOTRIMIN Market Analysis and Financial Projection

Last updated: February 4, 2026

Overview of LOTRIMIN

LOTRIMIN (clotrimazole) is an antifungal medication primarily used to treat fungal infections such as athlete's foot, jock itch, ringworm, and yeast infections. Available in topical formulations—creams, lotions, and powders—it is a well-established over-the-counter (OTC) drug with a high global market share in antifungal treatments.

---

Clinical Trials Status

Recent Development Activity

• As of 2023, no publicly registered clinical trials for new indications of LOTRIMIN have been announced or ongoing in major registries (ClinicalTrials.gov, WHO ICTRP).
• Historically, LOTRIMIN's core safety and efficacy profile have been confirmed through multiple trials for common fungal infections, with approval dating back to the 1970s.
• No recent phase I, II, or III trials have been registered to explore novel uses or formulations, indicating the drug is approaching market maturity.

Implications

• The absence of new clinical trials suggests current manufacturing and marketing focus remains on existing indications.
• Potential for future trials exists if companies seek approval for resistant strains, formulation improvements, or new delivery methods, but no data currently support ongoing research.

---

Market Analysis

Global Market Size and Trends

• The global antifungal market was valued at approximately USD 13 billion in 2022.
• The segment dominated by topical antifungals such as LOTRIMIN accounts for roughly USD 4.5 billion.
• Lotrimin holds a leading position among OTC antifungal brands due to its widespread availability and brand recognition.

Market Drivers

• Rising prevalence of fungal infections driven by increased immunosuppressive therapies, diabetes, and urbanization.
• Consumer shift toward OTC and self-medication options in dermatology.
• Expanding aging population, which is more susceptible to fungal skin conditions.

Market Challenges

• Competition from generic clotrimazole products and other antifungals such as terbinafine and miconazole.
• Increasing resistance to current antifungal agents in some fungal strains.
• Regulatory pressures on OTC drug formulations in key markets, including the U.S. and European Union.

Regional Breakdown (2022)

Region	Market Share	Growth Rate (Compound Annual Growth Rate, CAGR)	Key Factors
North America	40%	3.2%	High OTC usage, extensive healthcare infrastructure
Europe	25%	2.8%	Aging population, regulatory environment
Asia-Pacific	25%	6.0%	Increasing fungal infection incidence, rising OTC demand
Rest of World	10%	4.5%	Emerging markets, growing healthcare expenditure

---

Market Projections (2023–2030)

Forecast Highlights

• The antifungal market is projected to grow at a CAGR of 4.0% from 2023 to 2030.
• The topical antifungal segment, led by brands like LOTRIMIN, is expected to maintain a dominant share.
• Market penetration of new formulations or products targeting resistant fungi could accelerate growth.

Projected Market Value (2023–2030)

Year	Estimated Market Size	Notes
2023	USD 4.5 billion	Current market size for topical antifungals
2025	USD 5.2 billion	Market expansion driven by increased fungal infections
2030	USD 6.3 billion	Continued growth with potential formulation innovations

Key Factors Influencing Growth

• Patent expiries of brands and introduction of generic clotrimazole products.
• Increased investment in dermatological research.
• Potential new formulations (e.g., higher efficacy, longer-lasting action).

---

Strategic Considerations

• Product Differentiation: Opportunities for formulations that improve adherence, reduce application frequency, or target resistant fungi.
• Regulatory Strategies: Navigating OTC regulations in key markets remains crucial.
• Market Expansion: Focus on emerging markets and developing regions with increasing fungal infection incidence.
• Research Opportunities: Modest clinical research interest suggests limited pipeline for new indications. Investment could focus on resistant strains or novel drug delivery systems.

---

Key Takeaways

• Clinical trials: No recent or ongoing studies for new indications; existing data supports current uses.
• Market size: The global antifungal market was USD 13 billion in 2022, with topicals like LOTRIMIN dominating a USD 4.5 billion segment.
• Growth prospects: Forecasted CAGR of around 4% up to 2030; driven by rising fungal infections and OTC demand.
• Competitive environment: High competition with generics; resistance concerns may influence future opportunities.
• Innovation potential: Limited pipeline suggests ripe opportunities for product differentiation and formulations.

---

FAQs

1. Are there plans for new clinical trials for LOTRIMIN?

No public records indicate ongoing or planned trials; focus remains on existing formulations and indications.

2. How does LOTRIMIN compare to other antifungal drugs?

LOTRIMIN is among the leading OTC antifungals, with broad use for common fungal infections. Generic versions reduce market exclusivity but maintain its market presence.

3. What are the primary drivers of growth in the LOTRIMIN market?

Increased fungal infection incidence, consumer preference for OTC solutions, and demographic shifts such as aging populations.

4. What are the challenges facing LOTRIMIN's market?

Resistance development, competition from generics, regulatory hurdles, and potential market saturation.

5. Are there innovations expected in topical antifungals in the near term?

Limited pipeline activity suggests innovation is slow; however, advances in drug delivery systems and formulations targeting resistant strains are areas for potential growth.

---

References

1. MarketWatch. Global Antifungal Market Size, Share & Trends Analysis (2022).
2. ClinicalTrials.gov. Search for clotrimazole or LOTRIMIN-related trials.
3. World Health Organization. Global Overview of Fungal Infections (2021).
4. Grand View Research. Topical Antifungal Market Analysis, Forecast (2023).
5. U.S. FDA. Regulatory status of OTC antifungal drugs.